Monitor the resolution of the Mayne Pharma litigation over net working capital adjustments, as an adverse outcome could significantly impact the company's already limited cash reserves. The going concern warning from the auditor combined with the lack of accrual for potential losses suggests significant financial risk despite the revenue growth.
Price Chart
Executive Summary
This is an amended 10-K filing that corrects minor printer errors in the original filing. The amendment does not change any financial statements or disclosures. However, the filing reveals substantial doubt about the company's ability to continue as a going concern due to ongoing litigation with Mayne Pharma over net working capital adjustments and declining cash reserves, despite improved royalty revenue.
Key Facts
- Amendment corrects printer errors in Item 12, Item 15, and the Index to Financial Statements - no financial restatements
- Auditor change confirmed: Carr, Riggs & Ingram replaced Berkowitz Pollack Brant in January 2026
- Company has $7.5 million cash as of December 31, 2025, with substantial doubt about going concern for next 12 months
- Ongoing litigation with Mayne Pharma over net working capital allowances - no accrual made due to inability to estimate loss range
- License revenue increased 71.6% YoY to $3.022 million, but company reported net loss of $569 thousand for 2025
- Two patent infringement lawsuits ongoing against generic competitors for IMVEXXY (Teva and Sun Pharma)
Financial Impact
No financial impact from the amendment itself, but ongoing litigation with Mayne Pharma could materially affect future cash flows and royalty payments. Company has $7.5 million cash with substantial doubt about going concern.
Risk Factors
- Substantial doubt about ability to continue as a going concern
- Ongoing litigation with Mayne Pharma over net working capital adjustments
- Potential for generic competition to IMVEXXY which could reduce royalty rates
- Dependence on Mayne Pharma for patent enforcement and royalty payments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001213900-26-037918 |
| Document: ea027599202ex31-2.htm | 0001213900-26-037918 |
| Document: ea027599202ex31-1.htm | 0001213900-26-037918 |
| Document: ea027599202ex32-1.htm | 0001213900-26-037918 |
| Document: ea027599202ex32-2.htm | 0001213900-26-037918 |
| Document: ea027599202ex23-1.htm | 0001213900-26-037918 |
| Document: ea027599202ex23-2.htm | 0001213900-26-037918 |
| Document: 0001213900-26-037918-index-headers.html | 0001213900-26-037918 |
| Document: 0001213900-26-037918-index.html | 0001213900-26-037918 |
| Document: 0001213900-26-037918.txt | 0001213900-26-037918 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $2.08 $2.10 | ▼ −0.96% | ▼ −2.86% | $1.78 (+14.18%) |
May 12, 2026 23w ago | 8-K | $2.02 $1.82 | ▼ −9.90% | ▼ −9.29% | $1.78 (−11.63%) |
Mar 31, 2026 29w ago | 10-K/A | $2.00 $2.11 | ▼ −5.50% | ▲ +4.22% | $1.78 (+10.75%) |
Mar 30, 2026 30w ago | 8-K | $2.02 $2.10 | ▲ +3.96% | ▼ −5.46% | $1.78 (−11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers